US20080058641A1 - Imaging method, device and system - Google Patents
Imaging method, device and system Download PDFInfo
- Publication number
- US20080058641A1 US20080058641A1 US11/927,729 US92772907A US2008058641A1 US 20080058641 A1 US20080058641 A1 US 20080058641A1 US 92772907 A US92772907 A US 92772907A US 2008058641 A1 US2008058641 A1 US 2008058641A1
- Authority
- US
- United States
- Prior art keywords
- lesion
- fluid
- contrast agent
- debridement
- area
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
- A61B6/48—Diagnostic techniques
- A61B6/481—Diagnostic techniques involving the use of contrast agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/16—Bone cutting, breaking or removal means other than saws, e.g. Osteoclasts; Drills or chisels for bones; Trepans
- A61B17/1604—Chisels; Rongeurs; Punches; Stamps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/32—Surgical cutting instruments
- A61B17/3203—Fluid jet cutting instruments
- A61B17/32037—Fluid jet cutting instruments for removing obstructions from inner organs or blood vessels, e.g. for atherectomy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B50/00—Containers, covers, furniture or holders specially adapted for surgical or diagnostic appliances or instruments, e.g. sterile covers
- A61B50/30—Containers specially adapted for packaging, protecting, dispensing, collecting or disposing of surgical or diagnostic appliances or instruments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/36—Image-producing devices or illumination devices not otherwise provided for
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/0095—Packages or dispensers for prostheses or other implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30756—Cartilage endoprostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/48—Operating or control means, e.g. from outside the body, control of sphincters
- A61F2/488—Means for detecting or monitoring wear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/36—Image-producing devices or illumination devices not otherwise provided for
- A61B90/37—Surgical systems with images on a monitor during operation
- A61B2090/376—Surgical systems with images on a monitor during operation using X-rays, e.g. fluoroscopy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
- A61B2090/3933—Liquid markers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
- A61B6/44—Constructional features of apparatus for radiation diagnosis
- A61B6/4429—Constructional features of apparatus for radiation diagnosis related to the mounting of source units and detector units
- A61B6/4435—Constructional features of apparatus for radiation diagnosis related to the mounting of source units and detector units the source unit and the detector unit being coupled by a rigid structure
- A61B6/4441—Constructional features of apparatus for radiation diagnosis related to the mounting of source units and detector units the source unit and the detector unit being coupled by a rigid structure the rigid structure being a C-arm or U-arm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
- A61B6/48—Diagnostic techniques
- A61B6/486—Diagnostic techniques involving generating temporal series of image data
- A61B6/487—Diagnostic techniques involving generating temporal series of image data involving fluoroscopy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/32—Joints for the hip
- A61F2/34—Acetabular cups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/38—Joints for elbows or knees
- A61F2/3859—Femoral components
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/38—Joints for elbows or knees
- A61F2/389—Tibial components
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
- A61F2002/2835—Bone graft implants for filling a bony defect or an endoprosthesis cavity, e.g. by synthetic material or biological material
- A61F2002/2839—Bone plugs or bone graft dowels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30108—Shapes
- A61F2002/3011—Cross-sections or two-dimensional shapes
- A61F2002/30138—Convex polygonal shapes
- A61F2002/30158—Convex polygonal shapes trapezoidal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30667—Features concerning an interaction with the environment or a particular use of the prosthesis
- A61F2002/30673—Lubricating means, e.g. synovial pocket
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30756—Cartilage endoprostheses
- A61F2002/30759—Mosaicplasty, i.e. using a plurality of individual cartilage plugs for filling a substantial cartilage defect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30767—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth
- A61F2/30771—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth applied in original prostheses, e.g. holes or grooves
- A61F2002/30772—Apertures or holes, e.g. of circular cross section
- A61F2002/30784—Plurality of holes
- A61F2002/30785—Plurality of holes parallel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30767—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth
- A61F2/30771—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth applied in original prostheses, e.g. holes or grooves
- A61F2002/30772—Apertures or holes, e.g. of circular cross section
- A61F2002/30784—Plurality of holes
- A61F2002/30787—Plurality of holes inclined obliquely with respect to each other
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30767—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth
- A61F2/30771—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth applied in original prostheses, e.g. holes or grooves
- A61F2002/30878—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth applied in original prostheses, e.g. holes or grooves with non-sharp protrusions, for instance contacting the bone for anchoring, e.g. keels, pegs, pins, posts, shanks, stems, struts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/32—Joints for the hip
- A61F2/34—Acetabular cups
- A61F2002/3401—Acetabular cups with radial apertures, e.g. radial bores for receiving fixation screws
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/007—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests for contrast media
Definitions
- the invention relates generally to medical imaging and particularly to highlighting an osteolytic lesion and debridement of an imaged highlighted lesion.
- the invention relates to a method, device and kit for distinguishing and imaging a lesion for debridement.
- Osteolysis is a common complication in total hip arthroplasty and the most common cause of component failure. Osteolysis is a response to wear debris. It can develop around a hip or knee implant as a result of generation of wear debris, access of the particles to the implant-bone interface and the biologic response of the implant host to the particles. Osteolysis is mediated primary by macrophages. Fibroblasts and endothelial cells also play a role. These cells are activated by the wear debris, primarily polyethylene, but also metal and polymethylmethacrylate particles. The biologic reaction to these particles is a nonspecific foreign-body reaction.
- Particles in the submicron size range undergo phagocytosis by macrophages and release a variety of cytokines which ultimately stimulate osteoclasts to resorb bone.
- the most common source of wear debris is adhesive-abrasive wear between a femoral head and polyethylene liner. This wear can produce as many as 500,000 particles per gait cycle.
- Osteolysis can be asymptomatic until the lesions become very large. While some osteolytic lesions may be cleansed by washing and conventional debridement, surgery is a typical treatment. The surgery both treats the lesions and removes particles that could generate recurrence. With a stable acetabular component in acceptable alignment and with a modular liner, debridement and bone grafting of the lesions with retention of the acetabular shell and replacement of the polyethylene liner can be successful. However, if the acetabular shell is loose or malpositioned, then revision of the component is indicated.
- osteolytic lesions are not easily diagnosed because they can be hidden well within tissue near an implant. They can be hidden from x-tray visualization because they are near obscuring metal implant structure or the like. Or, simply the lesions are not sufficiently distinguished from adjacent tissue and structure to be visualized by usual detection mechanisms such as fluoroscopy.
- Successful substantially noninvasive treatment of osteolytic lesions requires that the lesion location including location and extent in an implant area be identified and imaged during debridement.
- the invention provides a method and kit for substantially noninvasively diagnosing an osteolytic lesion and a method and kit for distinguishing the location or extent of an osteolytic lesion for substantially noninvasively debridement of the lesion.
- a method for treatment of a lesion comprises: injecting a contrast agent into a body area to distinguish an osteolytic lesion for imaging; and delivering an effective amount of a debridement fluid to debride the distinguished lesion.
- a system or kit for treatment of a lesion comprises: a delivery device for injecting a contrast agent into a body area to distinguish an osteolytic lesion for imaging; a fluid reservoir, a debridement fluid contained within the fluid reservoir; a tubular conduit having a pickup end and delivery/aspirator end and first and second cannulas extending with one another longitudinally as part of the tubular conduit; the first cannula having at least one orifice at the delivery/aspirator end of the tubular conduit to deliver or aspirate debridement fluid to or from the distinguished lesion; and the second cannula substantially open at the delivery/aspirator end of the tubular conduit to deliver or aspirate fluid to or from the distinguished lesion; and an imaging device to monitor delivery of the debridement fluid to the distinguished lesion.
- a diagnostic procedure comprises: injecting a contrast agent into synovial fluid in a body area in need of treatment; and imaging a location or extent of a lesion in the area that has been distinguished by the contrast agent.
- a method of imaging an osteolytic lesion comprises injecting a contrast agent into synovial fluid in a vicinity of the osteolytic lesion; permitting contrast agent injected synovial fluid to circulate to the lesion; positioning an imaging device responsive to the contrast agent adjacent the vicinity of the osteolytic lesion; and imaging the osteolytic lesion distinguished by the contrast agent from adjacent tissue.
- FIGS. 1 through 4 are schematic representations of osteolytic lesion areas nearby hip and knee implants
- FIG. 5 is a schematic elevation of a lesion debridement device
- FIG. 6 is a cross-sectional side view of a tubular flexible delivery tube end of the FIG. 5 device
- FIG. 7 is a schematic side elevation of a pulse-generating mechanism for the debridement device
- FIG. 8 is a schematic perspective view of a user using a system or kit including a lesion debridement device and monitoring fluoroscope;
- FIG. 9 shows the hip joint of FIG. 1 in need of treatment for a lesion and placement of a debridement device to effect irrigation of the lesion
- the invention relates to a method that injects a contrast agent, preferably water miscible, into a contained normal anatomic cavity of the body in the vicinity of an implant.
- a contrast agent is injected into synovial fluid at a joint.
- Synovial fluid is a clear, thixotropic lubricating fluid secreted by membranes in joint cavities, tendon sheaths, and bursae.
- the injected fluid carries a contrast agent that renders a lesion radio-opaque or identifiable to available non-invasive imaging technology.
- the injected material can distribute evenly within the cavity space by way of diffusion. The distribution can be enhanced by external ultrasound application, or mechanical motion of the cavity space. For example, after injection into a knee, a patient can be asked to walk a number of paces to help distribute the injected material.
- lesions can form behind or around the implanted medical device. These lesions otherwise may be undetectable by conventional non-invasive imaging techniques.
- the injected contrast agent distributes within the fluid cavity. If a lesion communicates with the cavity, the material will also distribute to the previously un-identified lesion.
- the inventive method identifies a lesion that communicates with the fluid filled anatomic cavity, either by natural flow of the fluid around an implanted device or natural structure or through emplaced voids in a device such as the holes in an implanted cup.
- osteolytic lesions can communicate with the normal anatomic synovial joint space either around an implant or through holes in a hip implant.
- the synovial fluid is injected with a contrast agent, which then flows to the lesion and distinguishes to make it identifiable by non-invasive imaging.
- the agent can identify the lesion location and extent to permit debridement.
- Debridement can be by any suitable procedure for wound or lesion management including lavage, particularly pulse lavage or pulse irrigation is one.
- pulse lavage a pulsating water jet, is directed toward the wound or lesion area. This procedure is effective in removing debris and bacteria from wound and lesion areas.
- Pulse irrigation is used as part of a number of orthopedic procedures such as prosthetic joint replacement, in which it is used to remove bone fragments from an area of prosthesis.
- the debridement fluid of the invention can be water and other aqueous compositions, including any other typical irrigating or debridement solution.
- the fluid is a clear biocompatible debridement fluid such as warm isotonic saline or normal saline in combination with an antibiotic.
- the solution may include buffers and a bicarbonate, citric acid and tanic acid in very low concentrations.
- the fluid can be a gas and liquid mixture.
- the gas can be oxygen or carbon dioxide or hydrogen peroxide useful for sterilization purposes.
- the fluid can include steroid and anti-inflammatory mendicants.
- a preferred debridement fluid comprises a mixture of inorganic salts and minerals, compounded to mimic an electrolyte concentration and a body fluid mixture in an isotonic state.
- the fluid typically comprises a halide salt of lithium, sodium, potassium, calcium, and other cations.
- the halide is fluoride, chloride, bromide, or iodide, and most typically chloride.
- a typical electrolyzed solution has a pH within the range of about 2 to about 5, an oxidation reduction potential within the range of about +600 mV to about +1200 mV, and hypohalous acid concentration in the range of about 10 ppm to about 200 ppm.
- the solution can have bactericidal, fungicidal, and sporicidal properties.
- biosorbable means capable of being harmlessly taken up by the body and “biocompatible” means capable of harmlessly persisting in the body.
- biocompatible includes biosorbable materials.
- the debridement fluid of the invention can include a biocompatible particulate abrasive, which can be a biosorbable material that dissolves within several days.
- the abrasive is biosorbable and capable of passing through small gauge needles under lavage pressure.
- Calcium sulfate (CaSO 4 ) is a preferred material and may be obtained as MIIGTM from Wright Medical Technology, Inc. of Arlington, Tenn.
- the particulate abrasive can be present in the debridement fluid in a percent by weight between 0.1 and 65; desirably between 1 and 40 and preferably between 3 and 15.
- Other possible particulate abrasives include the materials disclosed in copending application, Shimko et al., (attorney docket P23148). For example, these include injectable forms of: calcium phosphate, tri-calcium phosphate, hydroxyapatite, coral hydroxyapatite, demineralized bone matrix, and mineralized bone matrix.
- the biosorbable material can be an injectable solid form of a biopolymer, for example, polylactic acid, polyglycolic acid, polygalactic acid, polycaprolactone, polyethylene oxide, polypropylene oxide, polysulfone, polyethylene, polypropylene, hyaluronic acid or bioglass.
- a biopolymer for example, polylactic acid, polyglycolic acid, polygalactic acid, polycaprolactone, polyethylene oxide, polypropylene oxide, polysulfone, polyethylene, polypropylene, hyaluronic acid or bioglass.
- An embodiment of the invention comprises following progress of the lesion debridement by fluoroscopy.
- contrast agent is injected into the lesion area through a catheter, or preferably through the inner expression cannula of the device of the invention along with debridement fluid.
- the contrast agent migrates so that the lesion can be radiographically imaged with a fluoroscope.
- the fluoroscope produces a planar (or two dimensional) image of the lesion area that can be evaluated to monitor the debridement method. This embodiment is discussed in further detail in conjunction with the drawings.
- FIG. 1 and FIG. 2 are views of a hip joint implant and FIG. 3 and FIG. 4 are respectively a tibia implant and a femur implant.
- FIG. 3 and FIG. 4 are respectively a tibia implant and a femur implant.
- FIG. 1 and FIG. 2 are anterior to posterior views of pelvis 212
- FIG. 3 is an anterior to posterior view of a knee implant into tibia 214
- FIG. 4 is a medial to lateral view of an implant into femur 216
- FIG. 1 and FIG. 2 how osteolytic lesions 218 , 220 buried deep within the pelvis 212 behind acetabular cup 122 of implant 224 .
- the acetabular cup 222 is also shown in detail in FIG. 1 .
- synovial fluid 228 within joint capsule 230 is in fluid communication with the lesion 220 around the cup 222 .
- the lesion 218 is completely buried behind the acetabular cup 222 .
- the fluid 228 is in communication with the lesion 220 through holes 226 in the cup 222 .
- Injector 232 which can be a syringe or other slender non-invasive delivery instrument is shown injected into the synovial fluid cavity 234 in each of the FIG. 1 and FIG. 2 .
- a contrast agent is injected into the synovial fluid 228 by the injector 232 .
- the contrast agent is delivered as a dissolved or suspended fluid that in turn is either dissolved or suspended in the synovial fluid 228 and is transported by the fluid 228 to the lesion 218 , 220 site where it radio-opaquely contrasts the lesion 218 , 220 .
- FIG. 3 and FIG. 4 illustrate other lesion locations that can be identified and controllably treated according to the invention.
- FIG. 3 is an anterior to posterior view of tibia 214 with implant 242 with screw holes 244 and upper polyethylene articular surface 246 .
- Lesion 248 has formed beneath the implant, substantially removed from view of any imaging technique.
- a contrast agent is injected by injector 232 into synovial fluid 228 above the polyethylene articular surface 246 .
- the contrast agent migrates with the fluid 228 through screw holes 244 and around the implant to the location of the lesion 248 .
- the lesion is stained for identification, again as described hereinafter with reference to FIGS. 5 through 9 .
- femur 216 is shows a particularly pernicious lesion 252 .
- the lesion 252 is situated within an outline of metal femur implant component 254 and is unobservable by any imaging technique.
- the contrast agent is injected by injector 232 into synovial fluid 228 , and then migrates to the lesion 252 with flow of the fluid 228 around the implant component 254 to highlight the lesion 252 .
- the contrasted lesions 218 , 220 , 248 and 252 are amenable to imaging diagnoses and fluoroscopic controlled debridement as described hereinafter with reference to FIGS. 5 through 9 .
- the contrast agent is a biocompatible material that is capable of being detected or monitored by fluoroscopy, x-ray photography, CAT scan, ultrasound or other such imaging techniques that can be used to detect and locate contrast distinguished tissue.
- the invention may be used as a diagnostic tool to identify and define previously unknown or undetected hard or soft orthopedic and skeletal lesions that communicate with normally occurring fluid filled anatomic spaces in the body, such as the synovial capsule surrounding articulating joints.
- the contrast agent is suspended or dissolved into a carrying fluid and is injected into the vicinity of a joint implant with suspected osteolytic lesions.
- Preferred contrast agents are radio-opaque materials.
- the contrast agent can be either water soluble or water insoluble. Examples of water soluble contrast agents include metrizamide, iopamidol, iothalamate sodium, iodomide sodium, iohexol and meglumine. Examples of water insoluble contrast agents include tantalum, tantalum oxide, and barium sulfate, each of which is commercially available. Other water insoluble contrast agents include gold, tungsten, and platinum powders. Some radio-opaque contrasting agents are available in liquid form.
- the contrast agent is water insoluble (i.e., has a water solubility of less than 0.01 mg/ml at 20° C.).
- the carrying fluid for the contrast agent can be water or other aqueous compositions.
- the fluid is a clear biocompatible fluid such as warm isotonic saline or normal saline.
- the solution may include materials such as an antibiotic, a buffer or a bicarbonate, citric acid and tanic acid in very low concentrations.
- a preferred carrying fluid comprises a mixture of inorganic salts and minerals, compounded to mimic an electrolyte concentration and a body fluid mixture in an isotonic state.
- the fluid typically comprises a halide salt of lithium, sodium, potassium, calcium, and other cations.
- the halide is fluoride, chloride, bromide, or iodide, and most typically chloride.
- a typical electrolyzed solution has a pH within the range of about 2 to about 5, an oxidation reduction potential within the range of about +600 mV to about +1200 mV, and hypohalous acid concentration in the range of about 10 ppm to about 200 ppm.
- the solution can have bactericidal, fungicidal, and sporicidal properties.
- the contrast agent can be dissolved or suspended in the carrying fluid in a weight percent from 0.001 mg/ml to 1000 mg/ml, desirably 0.01 mg/ml to 800 mg/ml, and preferably 0.1 mg/ml to 600 mg/ml.
- FIG. 5 shows a debridement device 10 for the washing and debridement of wounds and lesions of a patient.
- the system 10 includes housing 12 with conduit 14 for the delivery of fluid under pressure.
- inner expression cannula 18 and outer aspirator circumferential cannula 20 are shown longitudinally form the conduit 14 .
- the conduit 14 includes a flexible pickup section 22 and a rigid delivery section 24 .
- the system 10 includes a pressurized fluid reservoir 40 and a fluid transfer pump 50 , which is in fluid communication with inner expression cannula 18 and outer aspirator cannula line 20 .
- the conduit 14 has a pickup end 16 at fluid reservoir 50 to operatively connect the inner cannula 18 from the reservoir 40 (through fluid transfer pump 50 ) to fluid aspirator/expression end 26 of rigid section 24 .
- the outer aspirator cannula 20 is operatively connected from the fluid transfer pump 50 to fluid delivery/aspirator end 23 to fluid aspirator/discharge end 26 of rigid section 24 .
- the fluid within the reservoir 40 is a saline solution.
- the saline solution comprises 10 weight percent suspended calcium sulfate particulate having a particle size of about 150 microns.
- Fluid transfer pump 50 includes a drivable motor 52 having an elongated rotor shaft 54 .
- a fluid pressure generating pump 58 is arranged at a first end 56 of the rotor shaft 54 .
- the pump 58 provides fluid pressure to the dual cannula flexible tube 22 from reservoir 40 .
- a second end 60 of rotatable shaft 54 is attached to a suction pump 62 , also located within the housing 12 .
- Suction pump is in fluid communication with a screened disposable collection bottle 34 to provide a vacuum incentive of drainage of fluids to the bag 34 .
- a common empowered motor 52 with an extended shaft 54 provides drive for both pressure pump 58 and vacuum source 62 .
- the arrangement provides for a dual continuous pulsed feed of fluid to a patient lesion area shown in FIGS. 1 through 4 for a continuous withdrawal of fluid from the area after treatment of a wound or lesion.
- FIG. 6 is a cut away depiction of rigid delivery section 24 of the conduit 14 including inner cannula 18 and outer cannula 20 .
- Inner cannula 18 provides a passageway for fluid from fluid reservoir 40 .
- the fluid is expressed from syringe end 70 of the inner cannula 18 to a wound or lesion area.
- An outer wall 30 of conduit 14 forms outer cannula 20 with wall 26 of inner cannula 18 to provide a fluid passageway for aspirating fluid from wound or lesion area after lavage treatment.
- pulsating pump 84 has a rotating wheel 88 arranged to spin within sinusoidal inner surface 90 .
- the sinusoidal operation of the wheel 88 intermittently squeezes and releases flexible fluid feedline 92 .
- Feedline 92 includes pickup end 16 at fluid source 40 (shown in FIG. 5 ).
- a fluid feed section 96 extends to form inner expression cannula 18 , shown in FIG. 6 .
- Rotation of wheel 88 within the sinusoidal surface 90 generates intermittent pulses that are discharged through the pressured inner expression cannula 18 to be expressed at syringe end 70 .
- the suction side of the fluid transfer pump 50 is effected in a pulsed manner similar to the fluid pressure side.
- the suction or vacuum side 62 of the pump 50 can be in-phase or out-of-phase with the fluid pressure pulsating pump 58 .
- FIG. 9 shows the same pelvis 212 in need of treatment for a lesion 218 as described with reference to FIG. 1 . Additionally, FIG. 9 shows placement of aspirator/expression end 26 of the debridement device 10 to effect irrigation of the lesion 218 . Further, FIG. 8 illustrates fluoroscopic monitoring of the debridement.
- a user 112 is shown using a system or kit (delineated by dashed outline 110 ) including a support member 114 supporting a monitoring fluoroscope 116 , an image display 118 such as a flat panel television monitor and a lesion debridement device 10 .
- the user 112 grasps the rigid delivery section 24 of the debridement device 10 and inserts it into a hip joint 124 .
- Shown interiorly in FIG. 5 of a patient (the patient's outline beneath a sheet is indicated at 126 ).
- FIG. 9 shows a hip implant 224 that has been surgically implanted into the pelvis 212 .
- the implant 2324 may be of any form; for example, fixed, modular, primary, revision, ceramic head or metal head.
- implant 224 is well-fixed but in a diseased portion, osteolytic lesion 218 takes up space that would normally be filled with cancellous bone.
- Lesion 218 is soft and spongy. Though lesion 218 is depicted in this embodiment as being in the hip above acetabular cup 222 , it could be in the area of the implant 224 .
- Typical treatment to debride the lesion 218 is significant and invasive, sometimes involving removal of the implant 224 , open debridement of the lesion 218 (which enlarges the intramedullary area even further), and implantation of a revision implant.
- location of the lesion 218 is identified by fluoroscope or other imaging process, first and second holes are bored to access the lesion area and lavage fluid is expressed through one hole and is suctioned out the second hold. This procedure operates blindly without assurance that fluid expressed through the first hole delivers lavage to the lesion area.
- the lesion can be tough and resistant to a typical fluid that would be used in the first and second hole procedure.
- the present invention provides a minimally-invasive and accurate approach to treating lesions without removal of implants and revision and without two hole bodily invasion.
- the invention accurately delivers lavage to assure complete debridement of the lesion.
- a lavage fluid is utilized that comprises abrasive particles that completely debride even an osteolytic lesion that may be filled with resistant gelatinous masses of nacrotic and fibrous tissue.
- insertion of the rigid delivery section 24 of the debridement device into the hip joint, the orientation of the syringe expressing end 70 of the delivery section 24 ; impingement of expressed debridement fluid the lesion and aspirating of fluid containing the nacroic and fibrous tissue and spent fluid and particles can be monitored to assure complete debridement.
- the lesion debridement is monitored in FIG. 8 by viewing a fluoroscopic image of the hip joint 124 , lesion area 136 , and inserted rigid delivery section 14 .
- the patient 126 resides on table 120 , which is essentially transparent to x-rays.
- a support member 122 supports a fluoroscope and a television monitor 118 .
- the fluoroscope 116 can be supported by a C-shaped arm 142 device, as shown, Table 120 and patient 126 are positioned within the C formed by arm 142 .
- Fluoroscope 116 is an x-ray tube unit at a lower end of the C-shaped arm.
- the x-ray tube unit 116 emits an x-ray beam in a generally upward vertical direction through a diaphragm 146 .
- the x-ray beam is directed upward through the table 120 and the hip joint 124 of patient 126 .
- the x-ray beam is received by image intensifier 148 , which includes a television camera (not shown). A fluoroscopic field of view received by the camera at image intensifier 148 is projected on television monitor 118 .
- patient 126 is aligned between tube unit 116 and image intensifier 148 so that the internal patient's hip joint 124 is visible on television monitor 116 .
- User 112 performs a puncture of the patient's hip area toward the joint 124 with the elongated rigid delivery section 24 of debridement device 10 .
- the user 112 positions the puncture so that the inserted delivery section 24 syringe end is generally perpendicular to a central axis of an x-ray beam, which is directed upward from fluoroscope x-ray tube unit 116 to image intensifier 148 .
- the fluoroscopic field of view of fluoroscope 116 is then narrowed to display an image on monitor 116 to permit positioning aspirator/expression end 26 of delivery section 24 within the cancellous bone 134 of hip joint 124 at a location of the osteolytic lesion 136 .
- the user 112 manipulates the aspirator/expression end 26 of delivery section 24 , while remaining outside of the path of the x-ray beam between x-ray tube unit 116 and image intensifier 148 , as shown in FIG. 4 .
- the suer 112 views the location and orientation of aspirator/expression end 26 of delivery section 24 on television monitor 116 while activating the pulse lavage action of the debridement device 20 .
- the user 112 monitors the location and orientation of the aspirator/expression end 26 to express the particulate abrasive-containing lavage fluid from reservoir 40 .
- the user 112 delivers the debridement fluid and aspirates the fluid by alternating pulse lavage. This procedure effectively debrides the lesion 136 and intermittently aspirates resistant osteolytic lesion constituents including nacrotic and fibrous tissue and spent particulate abrasive-containing lavage fluid.
- the present invention is capable of variation and modification and therefore should not be limited to the precise details of the above examples.
- the invention relates to a kit that is packaged to include the above-described components for sale, shipment.
- the invention includes changes and alterations that fall within the purview of the following claims.
Abstract
A method, device and system or kit treat a lesion by injecting a contrasting agent into a body area to distinguish an osteolytic lesion for imaging; and delivering an effective amount of a debridement fluid to debride the distinguished lesion.
Description
- The invention relates generally to medical imaging and particularly to highlighting an osteolytic lesion and debridement of an imaged highlighted lesion. In an aspect, the invention relates to a method, device and kit for distinguishing and imaging a lesion for debridement.
- Osteolysis is a common complication in total hip arthroplasty and the most common cause of component failure. Osteolysis is a response to wear debris. It can develop around a hip or knee implant as a result of generation of wear debris, access of the particles to the implant-bone interface and the biologic response of the implant host to the particles. Osteolysis is mediated primary by macrophages. Fibroblasts and endothelial cells also play a role. These cells are activated by the wear debris, primarily polyethylene, but also metal and polymethylmethacrylate particles. The biologic reaction to these particles is a nonspecific foreign-body reaction. Particles in the submicron size range undergo phagocytosis by macrophages and release a variety of cytokines which ultimately stimulate osteoclasts to resorb bone. The most common source of wear debris is adhesive-abrasive wear between a femoral head and polyethylene liner. This wear can produce as many as 500,000 particles per gait cycle.
- Osteolysis can be asymptomatic until the lesions become very large. While some osteolytic lesions may be cleansed by washing and conventional debridement, surgery is a typical treatment. The surgery both treats the lesions and removes particles that could generate recurrence. With a stable acetabular component in acceptable alignment and with a modular liner, debridement and bone grafting of the lesions with retention of the acetabular shell and replacement of the polyethylene liner can be successful. However, if the acetabular shell is loose or malpositioned, then revision of the component is indicated.
- While washing and debridement procedures are preferred approaches to lesion management, these less invasive procedures are not always available. First, osteolytic lesions are not easily diagnosed because they can be hidden well within tissue near an implant. They can be hidden from x-tray visualization because they are near obscuring metal implant structure or the like. Or, simply the lesions are not sufficiently distinguished from adjacent tissue and structure to be visualized by usual detection mechanisms such as fluoroscopy. Successful substantially noninvasive treatment of osteolytic lesions requires that the lesion location including location and extent in an implant area be identified and imaged during debridement. Currently there are few strategies for reliably noninvasively locating and identifying lesions for debridement. There is a need for a method, device and system or kit for diagnosing osteolytic lesions and for visualizing the location and extent of an osteolytic lesion.
- The invention provides a method and kit for substantially noninvasively diagnosing an osteolytic lesion and a method and kit for distinguishing the location or extent of an osteolytic lesion for substantially noninvasively debridement of the lesion. According to the invention, a method for treatment of a lesion comprises: injecting a contrast agent into a body area to distinguish an osteolytic lesion for imaging; and delivering an effective amount of a debridement fluid to debride the distinguished lesion.
- A system or kit for treatment of a lesion comprises: a delivery device for injecting a contrast agent into a body area to distinguish an osteolytic lesion for imaging; a fluid reservoir, a debridement fluid contained within the fluid reservoir; a tubular conduit having a pickup end and delivery/aspirator end and first and second cannulas extending with one another longitudinally as part of the tubular conduit; the first cannula having at least one orifice at the delivery/aspirator end of the tubular conduit to deliver or aspirate debridement fluid to or from the distinguished lesion; and the second cannula substantially open at the delivery/aspirator end of the tubular conduit to deliver or aspirate fluid to or from the distinguished lesion; and an imaging device to monitor delivery of the debridement fluid to the distinguished lesion.
- In another embodiment, a diagnostic procedure comprises: injecting a contrast agent into synovial fluid in a body area in need of treatment; and imaging a location or extent of a lesion in the area that has been distinguished by the contrast agent.
- In still another embodiment, a method of imaging an osteolytic lesion comprises injecting a contrast agent into synovial fluid in a vicinity of the osteolytic lesion; permitting contrast agent injected synovial fluid to circulate to the lesion; positioning an imaging device responsive to the contrast agent adjacent the vicinity of the osteolytic lesion; and imaging the osteolytic lesion distinguished by the contrast agent from adjacent tissue.
-
FIGS. 1 through 4 are schematic representations of osteolytic lesion areas nearby hip and knee implants; -
FIG. 5 is a schematic elevation of a lesion debridement device; -
FIG. 6 is a cross-sectional side view of a tubular flexible delivery tube end of theFIG. 5 device; -
FIG. 7 is a schematic side elevation of a pulse-generating mechanism for the debridement device; -
FIG. 8 is a schematic perspective view of a user using a system or kit including a lesion debridement device and monitoring fluoroscope; and -
FIG. 9 shows the hip joint ofFIG. 1 in need of treatment for a lesion and placement of a debridement device to effect irrigation of the lesion - The invention relates to a method that injects a contrast agent, preferably water miscible, into a contained normal anatomic cavity of the body in the vicinity of an implant. In a preferred embodiment, a contrast agent is injected into synovial fluid at a joint. Synovial fluid is a clear, thixotropic lubricating fluid secreted by membranes in joint cavities, tendon sheaths, and bursae. The injected fluid carries a contrast agent that renders a lesion radio-opaque or identifiable to available non-invasive imaging technology. The injected material can distribute evenly within the cavity space by way of diffusion. The distribution can be enhanced by external ultrasound application, or mechanical motion of the cavity space. For example, after injection into a knee, a patient can be asked to walk a number of paces to help distribute the injected material.
- In the case of a knee or hip replacement, lesions can form behind or around the implanted medical device. These lesions otherwise may be undetectable by conventional non-invasive imaging techniques. The injected contrast agent distributes within the fluid cavity. If a lesion communicates with the cavity, the material will also distribute to the previously un-identified lesion. The inventive method identifies a lesion that communicates with the fluid filled anatomic cavity, either by natural flow of the fluid around an implanted device or natural structure or through emplaced voids in a device such as the holes in an implanted cup. For example, osteolytic lesions can communicate with the normal anatomic synovial joint space either around an implant or through holes in a hip implant. According to the invention, the synovial fluid is injected with a contrast agent, which then flows to the lesion and distinguishes to make it identifiable by non-invasive imaging. The agent can identify the lesion location and extent to permit debridement.
- Debridement can be by any suitable procedure for wound or lesion management including lavage, particularly pulse lavage or pulse irrigation is one. In pulse lavage, a pulsating water jet, is directed toward the wound or lesion area. This procedure is effective in removing debris and bacteria from wound and lesion areas. Pulse irrigation is used as part of a number of orthopedic procedures such as prosthetic joint replacement, in which it is used to remove bone fragments from an area of prosthesis.
- The debridement fluid of the invention can be water and other aqueous compositions, including any other typical irrigating or debridement solution. Preferably the fluid is a clear biocompatible debridement fluid such as warm isotonic saline or normal saline in combination with an antibiotic. However, many variations are possible. The solution may include buffers and a bicarbonate, citric acid and tanic acid in very low concentrations. Or the fluid can be a gas and liquid mixture. The gas can be oxygen or carbon dioxide or hydrogen peroxide useful for sterilization purposes. The fluid can include steroid and anti-inflammatory mendicants.
- A preferred debridement fluid comprises a mixture of inorganic salts and minerals, compounded to mimic an electrolyte concentration and a body fluid mixture in an isotonic state. The fluid typically comprises a halide salt of lithium, sodium, potassium, calcium, and other cations. Typically the halide is fluoride, chloride, bromide, or iodide, and most typically chloride. A typical electrolyzed solution has a pH within the range of about 2 to about 5, an oxidation reduction potential within the range of about +600 mV to about +1200 mV, and hypohalous acid concentration in the range of about 10 ppm to about 200 ppm. The solution can have bactericidal, fungicidal, and sporicidal properties.
- In this specification, “biosorbable” means capable of being harmlessly taken up by the body and “biocompatible” means capable of harmlessly persisting in the body. The term “biocompatible” includes biosorbable materials. The debridement fluid of the invention can include a biocompatible particulate abrasive, which can be a biosorbable material that dissolves within several days. Preferably, the abrasive is biosorbable and capable of passing through small gauge needles under lavage pressure. Calcium sulfate (CaSO4) is a preferred material and may be obtained as MIIG™ from Wright Medical Technology, Inc. of Arlington, Tenn. The particulate abrasive can be present in the debridement fluid in a percent by weight between 0.1 and 65; desirably between 1 and 40 and preferably between 3 and 15. Other possible particulate abrasives include the materials disclosed in copending application, Shimko et al., (attorney docket P23148). For example, these include injectable forms of: calcium phosphate, tri-calcium phosphate, hydroxyapatite, coral hydroxyapatite, demineralized bone matrix, and mineralized bone matrix. Further, the biosorbable material can be an injectable solid form of a biopolymer, for example, polylactic acid, polyglycolic acid, polygalactic acid, polycaprolactone, polyethylene oxide, polypropylene oxide, polysulfone, polyethylene, polypropylene, hyaluronic acid or bioglass.
- An embodiment of the invention comprises following progress of the lesion debridement by fluoroscopy. In this embodiment, contrast agent is injected into the lesion area through a catheter, or preferably through the inner expression cannula of the device of the invention along with debridement fluid. The contrast agent migrates so that the lesion can be radiographically imaged with a fluoroscope. The fluoroscope produces a planar (or two dimensional) image of the lesion area that can be evaluated to monitor the debridement method. This embodiment is discussed in further detail in conjunction with the drawings.
- These and other features of the invention will become apparent from the drawings and following detailed discussion, which by way of example without limitation describe preferred embodiments of the invention.
-
FIG. 1 andFIG. 2 are views of a hip joint implant andFIG. 3 andFIG. 4 are respectively a tibia implant and a femur implant. These figures illustrate the difficulty of diagnosing an osteolytic lesion and determining its location and orientation, particularly when in proximity to a metal implant as shown inFIG. 4 . In these figures, like structures are identified by the same part number. -
FIG. 1 andFIG. 2 are anterior to posterior views ofpelvis 212,FIG. 3 is an anterior to posterior view of a knee implant intotibia 214 andFIG. 4 is a medial to lateral view of an implant intofemur 216.FIG. 1 andFIG. 2 howosteolytic lesions pelvis 212 behind acetabular cup 122 ofimplant 224. Theacetabular cup 222 is also shown in detail inFIG. 1 . InFIG. 2 ,synovial fluid 228 withinjoint capsule 230 is in fluid communication with thelesion 220 around thecup 222. InFIG. 1 , thelesion 218 is completely buried behind theacetabular cup 222. However, the fluid 228 is in communication with thelesion 220 throughholes 226 in thecup 222.Injector 232, which can be a syringe or other slender non-invasive delivery instrument is shown injected into thesynovial fluid cavity 234 in each of theFIG. 1 andFIG. 2 . - In operation, a contrast agent is injected into the
synovial fluid 228 by theinjector 232. The contrast agent is delivered as a dissolved or suspended fluid that in turn is either dissolved or suspended in thesynovial fluid 228 and is transported by the fluid 228 to thelesion lesion -
FIG. 3 andFIG. 4 illustrate other lesion locations that can be identified and controllably treated according to the invention.FIG. 3 is an anterior to posterior view oftibia 214 withimplant 242 withscrew holes 244 and upper polyethylenearticular surface 246.Lesion 248 has formed beneath the implant, substantially removed from view of any imaging technique. A contrast agent is injected byinjector 232 intosynovial fluid 228 above the polyethylenearticular surface 246. The contrast agent migrates with the fluid 228 throughscrew holes 244 and around the implant to the location of thelesion 248. The lesion is stained for identification, again as described hereinafter with reference toFIGS. 5 through 9 . - In
FIG. 4 ,femur 216 is shows a particularlypernicious lesion 252. Thelesion 252 is situated within an outline of metalfemur implant component 254 and is unobservable by any imaging technique. In this case, the contrast agent is injected byinjector 232 intosynovial fluid 228, and then migrates to thelesion 252 with flow of the fluid 228 around theimplant component 254 to highlight thelesion 252. - The contrasted
lesions FIGS. 5 through 9 . - The contrast agent is a biocompatible material that is capable of being detected or monitored by fluoroscopy, x-ray photography, CAT scan, ultrasound or other such imaging techniques that can be used to detect and locate contrast distinguished tissue. The invention may be used as a diagnostic tool to identify and define previously unknown or undetected hard or soft orthopedic and skeletal lesions that communicate with normally occurring fluid filled anatomic spaces in the body, such as the synovial capsule surrounding articulating joints.
- The contrast agent is suspended or dissolved into a carrying fluid and is injected into the vicinity of a joint implant with suspected osteolytic lesions. Preferred contrast agents are radio-opaque materials. The contrast agent can be either water soluble or water insoluble. Examples of water soluble contrast agents include metrizamide, iopamidol, iothalamate sodium, iodomide sodium, iohexol and meglumine. Examples of water insoluble contrast agents include tantalum, tantalum oxide, and barium sulfate, each of which is commercially available. Other water insoluble contrast agents include gold, tungsten, and platinum powders. Some radio-opaque contrasting agents are available in liquid form. These include, for example, OMNIPAQUE from Nycomed, Inc., Princeton, N.J. Preferably, the contrast agent is water insoluble (i.e., has a water solubility of less than 0.01 mg/ml at 20° C.).
- The carrying fluid for the contrast agent can be water or other aqueous compositions. Preferably the fluid is a clear biocompatible fluid such as warm isotonic saline or normal saline. However, many variations are possible. The solution may include materials such as an antibiotic, a buffer or a bicarbonate, citric acid and tanic acid in very low concentrations.
- As with the debridement fluid, a preferred carrying fluid comprises a mixture of inorganic salts and minerals, compounded to mimic an electrolyte concentration and a body fluid mixture in an isotonic state. The fluid typically comprises a halide salt of lithium, sodium, potassium, calcium, and other cations. Typically the halide is fluoride, chloride, bromide, or iodide, and most typically chloride. A typical electrolyzed solution has a pH within the range of about 2 to about 5, an oxidation reduction potential within the range of about +600 mV to about +1200 mV, and hypohalous acid concentration in the range of about 10 ppm to about 200 ppm. The solution can have bactericidal, fungicidal, and sporicidal properties.
- The contrast agent can be dissolved or suspended in the carrying fluid in a weight percent from 0.001 mg/ml to 1000 mg/ml, desirably 0.01 mg/ml to 800 mg/ml, and preferably 0.1 mg/ml to 600 mg/ml.
-
FIG. 5 shows adebridement device 10 for the washing and debridement of wounds and lesions of a patient. Thesystem 10 includes housing 12 withconduit 14 for the delivery of fluid under pressure. With reference toFIGS. 1 and 2 ,inner expression cannula 18 and outer aspiratorcircumferential cannula 20 are shown longitudinally form theconduit 14. Theconduit 14 includes aflexible pickup section 22 and arigid delivery section 24. Thesystem 10 includes apressurized fluid reservoir 40 and afluid transfer pump 50, which is in fluid communication withinner expression cannula 18 and outeraspirator cannula line 20. - The
conduit 14 has apickup end 16 atfluid reservoir 50 to operatively connect theinner cannula 18 from the reservoir 40 (through fluid transfer pump 50) to fluid aspirator/expression end 26 ofrigid section 24. Theouter aspirator cannula 20 is operatively connected from thefluid transfer pump 50 to fluid delivery/aspirator end 23 to fluid aspirator/discharge end 26 ofrigid section 24. In this example, the fluid within thereservoir 40 is a saline solution. The saline solution comprises 10 weight percent suspended calcium sulfate particulate having a particle size of about 150 microns. -
Fluid transfer pump 50 includes adrivable motor 52 having anelongated rotor shaft 54. A fluidpressure generating pump 58 is arranged at afirst end 56 of therotor shaft 54. Thepump 58 provides fluid pressure to the dual cannulaflexible tube 22 fromreservoir 40. Asecond end 60 ofrotatable shaft 54 is attached to asuction pump 62, also located within the housing 12. Suction pump is in fluid communication with a screeneddisposable collection bottle 34 to provide a vacuum incentive of drainage of fluids to thebag 34. In this embodiment, a common empoweredmotor 52 with anextended shaft 54 provides drive for bothpressure pump 58 andvacuum source 62. The arrangement provides for a dual continuous pulsed feed of fluid to a patient lesion area shown inFIGS. 1 through 4 for a continuous withdrawal of fluid from the area after treatment of a wound or lesion. -
FIG. 6 is a cut away depiction ofrigid delivery section 24 of theconduit 14 includinginner cannula 18 andouter cannula 20.Inner cannula 18 provides a passageway for fluid fromfluid reservoir 40. The fluid is expressed fromsyringe end 70 of theinner cannula 18 to a wound or lesion area. Anouter wall 30 ofconduit 14 formsouter cannula 20 withwall 26 ofinner cannula 18 to provide a fluid passageway for aspirating fluid from wound or lesion area after lavage treatment. - In an embodiment shown in
FIG. 7 , pulsatingpump 84 has a rotating wheel 88 arranged to spin within sinusoidalinner surface 90. The sinusoidal operation of the wheel 88 intermittently squeezes and releasesflexible fluid feedline 92.Feedline 92 includespickup end 16 at fluid source 40 (shown inFIG. 5 ). A fluid feed section 96 extends to forminner expression cannula 18, shown inFIG. 6 . Rotation of wheel 88 within thesinusoidal surface 90 generates intermittent pulses that are discharged through the pressuredinner expression cannula 18 to be expressed atsyringe end 70. In an embodiment, the suction side of thefluid transfer pump 50 is effected in a pulsed manner similar to the fluid pressure side. The suction orvacuum side 62 of thepump 50 can be in-phase or out-of-phase with the fluidpressure pulsating pump 58. -
FIG. 9 shows thesame pelvis 212 in need of treatment for alesion 218 as described with reference toFIG. 1 . Additionally,FIG. 9 shows placement of aspirator/expression end 26 of thedebridement device 10 to effect irrigation of thelesion 218. Further,FIG. 8 illustrates fluoroscopic monitoring of the debridement. - First, referring to
FIG. 8 , auser 112 is shown using a system or kit (delineated by dashed outline 110) including asupport member 114 supporting amonitoring fluoroscope 116, animage display 118 such as a flat panel television monitor and alesion debridement device 10. Theuser 112 grasps therigid delivery section 24 of thedebridement device 10 and inserts it into ahip joint 124. Shown interiorly inFIG. 5 , of a patient (the patient's outline beneath a sheet is indicated at 126). -
FIG. 9 shows ahip implant 224 that has been surgically implanted into thepelvis 212. The implant 2324 may be of any form; for example, fixed, modular, primary, revision, ceramic head or metal head. In non-diseased portions ofpelvis 212,implant 224 is well-fixed but in a diseased portion,osteolytic lesion 218 takes up space that would normally be filled with cancellous bone.Lesion 218 is soft and spongy. Thoughlesion 218 is depicted in this embodiment as being in the hip aboveacetabular cup 222, it could be in the area of theimplant 224. - Typical treatment to debride the
lesion 218 is significant and invasive, sometimes involving removal of theimplant 224, open debridement of the lesion 218 (which enlarges the intramedullary area even further), and implantation of a revision implant. In another typical treatment, location of thelesion 218 is identified by fluoroscope or other imaging process, first and second holes are bored to access the lesion area and lavage fluid is expressed through one hole and is suctioned out the second hold. This procedure operates blindly without assurance that fluid expressed through the first hole delivers lavage to the lesion area. Additionally, the lesion can be tough and resistant to a typical fluid that would be used in the first and second hole procedure. - The present invention provides a minimally-invasive and accurate approach to treating lesions without removal of implants and revision and without two hole bodily invasion. The invention accurately delivers lavage to assure complete debridement of the lesion. In the present invention, a lavage fluid is utilized that comprises abrasive particles that completely debride even an osteolytic lesion that may be filled with resistant gelatinous masses of nacrotic and fibrous tissue. Additionally, in an embodiment of the invention, insertion of the
rigid delivery section 24 of the debridement device into the hip joint, the orientation of thesyringe expressing end 70 of thedelivery section 24; impingement of expressed debridement fluid the lesion and aspirating of fluid containing the nacroic and fibrous tissue and spent fluid and particles can be monitored to assure complete debridement. - The lesion debridement is monitored in
FIG. 8 by viewing a fluoroscopic image of thehip joint 124, lesion area 136, and insertedrigid delivery section 14. Thepatient 126 resides on table 120, which is essentially transparent to x-rays. A support member 122 supports a fluoroscope and atelevision monitor 118. Thefluoroscope 116 can be supported by a C-shapedarm 142 device, as shown, Table 120 andpatient 126 are positioned within the C formed byarm 142.Fluoroscope 116 is an x-ray tube unit at a lower end of the C-shaped arm. Thex-ray tube unit 116 emits an x-ray beam in a generally upward vertical direction through adiaphragm 146. The x-ray beam is directed upward through the table 120 and thehip joint 124 ofpatient 126. The x-ray beam is received byimage intensifier 148, which includes a television camera (not shown). A fluoroscopic field of view received by the camera atimage intensifier 148 is projected ontelevision monitor 118. - In operation,
patient 126 is aligned betweentube unit 116 andimage intensifier 148 so that the internal patient'ship joint 124 is visible ontelevision monitor 116.User 112 performs a puncture of the patient's hip area toward the joint 124 with the elongatedrigid delivery section 24 ofdebridement device 10. Theuser 112 positions the puncture so that the inserteddelivery section 24 syringe end is generally perpendicular to a central axis of an x-ray beam, which is directed upward from fluoroscopex-ray tube unit 116 toimage intensifier 148. The fluoroscopic field of view offluoroscope 116 is then narrowed to display an image onmonitor 116 to permit positioning aspirator/expression end 26 ofdelivery section 24 within the cancellous bone 134 of hip joint 124 at a location of the osteolytic lesion 136. - The
user 112 manipulates the aspirator/expression end 26 ofdelivery section 24, while remaining outside of the path of the x-ray beam betweenx-ray tube unit 116 andimage intensifier 148, as shown inFIG. 4 . Thesuer 112 views the location and orientation of aspirator/expression end 26 ofdelivery section 24 ontelevision monitor 116 while activating the pulse lavage action of thedebridement device 20. Throughout the procedure, theuser 112 monitors the location and orientation of the aspirator/expression end 26 to express the particulate abrasive-containing lavage fluid fromreservoir 40. In an embodiment, theuser 112 delivers the debridement fluid and aspirates the fluid by alternating pulse lavage. This procedure effectively debrides the lesion 136 and intermittently aspirates resistant osteolytic lesion constituents including nacrotic and fibrous tissue and spent particulate abrasive-containing lavage fluid. - While preferred embodiments of the invention have been described, the present invention is capable of variation and modification and therefore should not be limited to the precise details of the above examples. For example, the invention relates to a kit that is packaged to include the above-described components for sale, shipment. The invention includes changes and alterations that fall within the purview of the following claims.
Claims (21)
1. to 30. (canceled)
31. A method of imaging an osteolytic lesion, comprising:
injecting a contrast agent into synovial fluid in a vicinity of the osteolytic lesion;
permitting contrast agent injected synovial fluid to circulate to the lesion;
positioning an imaging device responsive to the contrast agent adjacent the vicinity of the osteolytic lesion; and
imaging the osteolytic lesion distinguished by the contrast agent from adjacent tissue.
32. The method of claim 31 , wherein the osteolytic lesion is fluoroscopically imaged and a location and orientation of a debridement delivery device is adjusted according to location or extent of the fluoroscopic image.
33. The method of claim 31 , wherein the vicinity is a knee or hip joint space.
34. The method of claim 31 , wherein injecting the contrast agent comprises: positioning an injection catheter into the vicinity of the osteoloytic lesion; and injecting the contrast agent into synovial fluid in the vicinity through the injection catheter.
35. The method of claim 31 , further comprising effecting debridement of the distinguished lesion by a pulse lavage process.
36. The method of claim 31 , further comprising: emitting x-rays from the imaging device toward the distinguished lesion, detecting x-rays that have traversed the lesion, constructing a tomographic image from signals that are responsive to the detected x-rays to generate a real-time fluoroscopic image on a display monitor depicting the distinguished lesion and the relationship of a delivery/aspirator end of a debridement device to the area; and adjusting the location and orientation of the delivery/aspirator end of the debridement device according to the display monitor image to debride the lesion.
37. The method of claim 31 , further comprising delivering an effective amount of a debridement fluid to debride the distinguished lesion.
38. The method of claim 31 , comprising injecting the contrast agent into synovial fluid in the body area that is in fluid communication with the osteolytic lesion, wherein the contrast agent migrates to the lesion by flow or diffusion.
39. The method of claim 31 , comprising injecting the contrast agent into synovial fluid in the body area that is in fluid communication with the osteolytic lesion, wherein the contrast agent migrates to the lesion by flow or diffusion; and imaging a location or extent of a lesion in the area that has been distinguished by the contrasting agent.
40. The method of claim 31 , comprising injecting the contrast agent into synovial fluid in the body area that is in fluid communication with the osteolytic lesion, wherein the contrast agent migrates to the lesion by flow or diffusion; imaging a location or extent of a lesion in the area that has been distinguished by the contrasting agent; and controlling debridement of the osteolytic lesion according to the imaging.
41. The method of claim 31 , comprising injecting the contrast agent into synovial fluid in the body area that is in fluid communication with the osteolytic lesion, wherein the contrast agent migrates to the lesion by flow or diffusion; imaging a location or extent of a lesion in the area that has been distinguished by the contrasting agent; and controlling debridement of the osteolytic lesion according to the imaging; wherein the debridement comprises delivering a debridement fluid and intermittently aspirating the fluid by pulse lavage.
42. The method of claim 31 , comprising injecting the contrast agent into synovial fluid in the body area that is in fluid communication with the osteolytic lesion, wherein the contrast agent migrates to the lesion by flow or diffusion; imaging a location or extent of a lesion in the area that has been distinguished by the contrasting agent; and controlling debridement of the osteolytic lesion according to the imaging; wherein the debridement comprises delivering of a fluid with suspended particulate abrasive and the delivering is adjusted according to the imaging to direct the fluid with suspended particulate to the lesion area.
43. The method of claim 31 , further comprising: emitting x-rays toward the lesion area, detecting x-rays that have traversed the lesion area, constructing a real-time fluoroscopic image of delivering fluid and the lesion area from signals that are responsive to the detected x-rays; adjusting the delivering of the debridement fluid according to the fluoroscopic image to debride to lesion.
44. The method of claim 31 , wherein the contrast agent comprises a biosorbable material that is capable of being detected or monitored by fluoroscopy, x-ray photography, CAT scan or ultrasound.
45. The method of claim 31 , wherein the contrast agent comprises a biosorbable material that is capable of being detected or monitored by fluoroscopy, x-ray photography, CAT scan or ultrasound suspended or dissolved in a carrying fluid.
46. A debridement system, comprising:
a fluid reservoir for a debridement fluid containing a contrast agent;
a delivery section comprising; an expression cannula connected to the reservoir and an aspirator cannula concentric to the expression cannula; and
an imaging device responsive to contrast agent injected from the reservoir by the delivery section.
47. The system of claim 47 , wherein the delivery section comprises a tubular conduit having a pickup end and delivery/aspirator end and first and second cannulas extending with one another longitudinally as part of the tubular conduit; the first cannula having at least one orifice at the delivery/aspirator end of the tubular conduit to deliver or aspirate debridement fluid to or from the distinguished lesion; and the second cannula substantially open at the delivery/aspirator end of the tubular conduit to deliver or aspirate fluid to or from the distinguished lesion.
48. The system of claim 46 , wherein the imaging device comprises a fluoroscopy imaging device that includes an x-ray source oriented to emit x-rays toward the lesion area; a radiation detector that detects x-rays from the source that have traversed the lesion area; an image display to generate a real-time fluoroscopic image showing the relationship of the delivery/aspirator end of the tubular conduit to the area on a display monitor from signals that are responsive to the detected x-rays.
49. The system of claim 46 , wherein the contrast agent comprises a biosorbable material suspended or dissolved in a carrying fluid.
50. The system of claim 46 , wherein the contrast agent comprises a biosorbable material that is capable of being detected or monitored by fluoroscopy, x-ray photography, CAT scan or ultrasound.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/927,729 US20080058641A1 (en) | 2005-12-07 | 2007-10-30 | Imaging method, device and system |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/295,639 US20070129630A1 (en) | 2005-12-07 | 2005-12-07 | Imaging method, device and system |
US11/927,729 US20080058641A1 (en) | 2005-12-07 | 2007-10-30 | Imaging method, device and system |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/295,639 Division US20070129630A1 (en) | 2005-12-07 | 2005-12-07 | Imaging method, device and system |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080058641A1 true US20080058641A1 (en) | 2008-03-06 |
Family
ID=37983894
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/295,639 Abandoned US20070129630A1 (en) | 2005-12-07 | 2005-12-07 | Imaging method, device and system |
US11/927,729 Abandoned US20080058641A1 (en) | 2005-12-07 | 2007-10-30 | Imaging method, device and system |
US12/183,866 Active 2028-10-24 US8795361B2 (en) | 2005-12-07 | 2008-07-31 | Osteochondral plug graft, kit and method |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/295,639 Abandoned US20070129630A1 (en) | 2005-12-07 | 2005-12-07 | Imaging method, device and system |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/183,866 Active 2028-10-24 US8795361B2 (en) | 2005-12-07 | 2008-07-31 | Osteochondral plug graft, kit and method |
Country Status (2)
Country | Link |
---|---|
US (3) | US20070129630A1 (en) |
WO (1) | WO2007067920A2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070129630A1 (en) * | 2005-12-07 | 2007-06-07 | Shimko Daniel A | Imaging method, device and system |
US20070135706A1 (en) * | 2005-12-13 | 2007-06-14 | Shimko Daniel A | Debridement method, device and kit |
US20120310085A1 (en) * | 2011-06-02 | 2012-12-06 | Herweck Steve A | Body lumen fluid delivery device |
US10918398B2 (en) | 2016-11-18 | 2021-02-16 | Stryker Corporation | Method and apparatus for treating a joint, including the treatment of cam-type femoroacetabular impingement in a hip joint and pincer-type femoroacetabular impingement in a hip joint |
US11464569B2 (en) | 2018-01-29 | 2022-10-11 | Stryker Corporation | Systems and methods for pre-operative visualization of a joint |
US11957418B2 (en) | 2022-10-10 | 2024-04-16 | Stryker Corporation | Systems and methods for pre-operative visualization of a joint |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7067123B2 (en) | 2003-04-29 | 2006-06-27 | Musculoskeletal Transplant Foundation | Glue for cartilage repair |
US7901457B2 (en) | 2003-05-16 | 2011-03-08 | Musculoskeletal Transplant Foundation | Cartilage allograft plug |
US7837740B2 (en) | 2007-01-24 | 2010-11-23 | Musculoskeletal Transplant Foundation | Two piece cancellous construct for cartilage repair |
US7815926B2 (en) | 2005-07-11 | 2010-10-19 | Musculoskeletal Transplant Foundation | Implant for articular cartilage repair |
US8921109B2 (en) | 2005-09-19 | 2014-12-30 | Histogenics Corporation | Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof |
US8435551B2 (en) | 2007-03-06 | 2013-05-07 | Musculoskeletal Transplant Foundation | Cancellous construct with support ring for repair of osteochondral defects |
US9044542B2 (en) | 2007-12-21 | 2015-06-02 | Carticept Medical, Inc. | Imaging-guided anesthesia injection systems and methods |
US8545440B2 (en) | 2007-12-21 | 2013-10-01 | Carticept Medical, Inc. | Injection system for delivering multiple fluids within the anatomy |
WO2009086182A1 (en) | 2007-12-21 | 2009-07-09 | Carticept Medical, Inc. | Articular injection system |
EP2265220A1 (en) | 2008-03-05 | 2010-12-29 | Musculoskeletal Transplant Foundation | Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles |
US8152846B2 (en) * | 2008-03-06 | 2012-04-10 | Musculoskeletal Transplant Foundation | Instrumentation and method for repair of meniscus tissue |
US8801725B2 (en) | 2008-03-10 | 2014-08-12 | Zimmer Orthobiologics, Inc. | Instruments and methods used when repairing a defect on a tissue surface |
CA2753429A1 (en) * | 2009-02-24 | 2010-09-02 | Smith & Nephew, Inc. | Method and apparatus for fai surgeries |
US9113916B2 (en) | 2010-08-31 | 2015-08-25 | Zimmer, Inc. | Drill bit for osteochondral drilling with guiding element and uses thereof |
US8435305B2 (en) | 2010-08-31 | 2013-05-07 | Zimmer, Inc. | Osteochondral graft delivery device and uses thereof |
US8641718B2 (en) | 2010-10-19 | 2014-02-04 | Biomet Manufacturing, Llc | Method and apparatus for harvesting cartilage for treatment of a cartilage defect |
US8771353B2 (en) * | 2011-03-08 | 2014-07-08 | DePuy Synthes Products, LLC | Method and implant for replacing damaged meniscal tissue |
US20150289889A1 (en) * | 2012-11-12 | 2015-10-15 | Cartiheal (2009) Ltd. | Tools and Systems for Solid Form and Graft Implantation |
EP2967633B1 (en) * | 2013-03-15 | 2018-04-25 | Edge Systems LLC | Devices for treating the skin |
WO2015171754A1 (en) * | 2014-05-07 | 2015-11-12 | Massachusetts Institute Of Technology | Debridement apparatus using linear lorentz-force motors |
US10077420B2 (en) | 2014-12-02 | 2018-09-18 | Histogenics Corporation | Cell and tissue culture container |
WO2017035506A1 (en) * | 2015-08-27 | 2017-03-02 | Institute of Orthopedic Research & Education | Modification of the surface topography of cartilage grafts for joint reconstruction |
EP3359088A4 (en) * | 2015-10-05 | 2020-03-04 | Formae Inc. | Medical implant and anchoring system for a medical implant |
JP2022543820A (en) * | 2019-08-06 | 2022-10-14 | マイクロベンション インコーポレイテッド | Syringe |
Citations (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3288140A (en) * | 1963-10-04 | 1966-11-29 | John J Mccarthy | Means for treating surface wounds |
US3982017A (en) * | 1971-02-08 | 1976-09-21 | Thiele Geraldine H | Injectable solutions and processes of using such |
US4278078A (en) * | 1980-02-26 | 1981-07-14 | Stryker Corporation | Lavage handpiece |
US4655197A (en) * | 1982-12-01 | 1987-04-07 | Snyder Laboratories, Inc. | Lavage system with variable frequency, flow rate and pressure |
US4692140A (en) * | 1985-07-01 | 1987-09-08 | Snyder Laboratories, Inc. | Lavage/suction tip with dual splash shield |
US4781217A (en) * | 1985-02-13 | 1988-11-01 | Peretz Rosenberg | Pulse-irrigation method and apparatus |
US5077048A (en) * | 1988-07-13 | 1991-12-31 | Morishita Pharmaceutical Co., Ltd. | Bowel lavage composition |
US5127920A (en) * | 1987-03-27 | 1992-07-07 | Macarthur A Creig | Prosthesis and methods for subtotal dome arthroplasty of the hip joint |
US5200430A (en) * | 1991-03-21 | 1993-04-06 | Escalon Ophthalmics, Inc. | Debridement of bodily cavities using debridement fluids |
US5306237A (en) * | 1989-11-06 | 1994-04-26 | Mectra Labs, Inc. | Disposable lavage |
US5312385A (en) * | 1991-10-09 | 1994-05-17 | University Of Pittsburgh | Device for protected pulse irrigation |
US5499970A (en) * | 1994-08-23 | 1996-03-19 | Zimmer, Inc. | Debridement tip |
US5795324A (en) * | 1994-12-27 | 1998-08-18 | The United States Of America As Represented By The Secretary Of The Air Force | Wound and lavage irrigation cap apparatus and method for using |
US5817046A (en) * | 1997-07-14 | 1998-10-06 | Delcath Systems, Inc. | Apparatus and method for isolated pelvic perfusion |
US5931820A (en) * | 1994-12-27 | 1999-08-03 | The United States Of America As Represented By The Secretary Of The Air Force | Wound and lavage irrigation connector apparatus and method for using |
US5944748A (en) * | 1996-07-25 | 1999-08-31 | Light Medicine, Inc. | Photodynamic therapy apparatus and methods |
US5968017A (en) * | 1997-10-14 | 1999-10-19 | Merit Medical Systems, Inc. | Pulse fluid infusion systems |
US6001895A (en) * | 1993-03-22 | 1999-12-14 | Johnson & Johnson Medical, Inc. | Composite surgical material |
US6097978A (en) * | 1997-07-03 | 2000-08-01 | Medtronic Inc. | Measurement confirmation devices and methods for fluoroscopically directed surgery |
US6183497B1 (en) * | 1998-05-01 | 2001-02-06 | Sub-Q, Inc. | Absorbable sponge with contrasting agent |
US6190642B1 (en) * | 1988-02-19 | 2001-02-20 | Dentsply Research & Development Corp. | Irrigating and lavage compositions |
US20010018614A1 (en) * | 1999-03-16 | 2001-08-30 | Bianchi John R. | Implants for orthopedic applications |
US6364526B2 (en) * | 1997-11-26 | 2002-04-02 | Philips Medical Systems (Cleveland) Inc. | Fluoro-assist feature for a diagnostic imaging device |
US6471683B2 (en) * | 1990-08-06 | 2002-10-29 | Possis Medical, Inc. | Thrombectomy and tissue removal method |
US6496717B2 (en) * | 1998-10-06 | 2002-12-17 | University Of South Florida | Radio guided seed localization of imaged lesions |
US20030008011A1 (en) * | 2001-06-22 | 2003-01-09 | Mershon Millard Marsden | Compositions and methods for reducing blood and fluid loss from open wounds |
US6527760B1 (en) * | 2000-09-25 | 2003-03-04 | Vijay B. Vad | Out-patient joint lavage kit and protocol |
US6569147B1 (en) * | 1996-07-26 | 2003-05-27 | Kensey Nash Corporation | Systems and methods of use for delivering beneficial agents for revascularizing stenotic bypass grafts and other occluded blood vessels and for other purposes |
US20030105402A1 (en) * | 2001-09-12 | 2003-06-05 | Manoa Medical, Inc., A Delaware Corporation | Ultrasound imaging of breast tissue using ultrasound contrast agent |
US20030163081A1 (en) * | 2002-02-28 | 2003-08-28 | Constantz Brent R. | Localized fluid delivery devices having a porous applicator and methods for using the same |
US20030185903A1 (en) * | 2002-03-29 | 2003-10-02 | Jantzen Cole | Bone graft substitute composition |
US20030185704A1 (en) * | 2000-01-12 | 2003-10-02 | Suzanne Bernard | Physiologically balanced, ionized, acidic solution and methodology for use in wound healing |
US6635035B1 (en) * | 2000-05-02 | 2003-10-21 | Patrick V. Marasco | Tissue irrigation arrangement |
US20030229306A1 (en) * | 2002-03-29 | 2003-12-11 | Roger Sherman | Nasal lavage system and method |
US20040059284A1 (en) * | 2002-09-24 | 2004-03-25 | Nash John E. | Interventional procedure drive and control system |
US6726712B1 (en) * | 1999-05-14 | 2004-04-27 | Boston Scientific Scimed | Prosthesis deployment device with translucent distal end |
US6740120B1 (en) * | 1996-08-13 | 2004-05-25 | James B. Grimes | Bone prosthesis and method of Access |
US6746401B2 (en) * | 2002-05-06 | 2004-06-08 | Scimed Life Systems, Inc. | Tissue ablation visualization |
US20040162476A1 (en) * | 2001-06-06 | 2004-08-19 | Lars Selander | Positioning device for x-ray examinations |
US20040162488A1 (en) * | 1994-09-21 | 2004-08-19 | Medrad, Inc. | Patient specific dosing contrast delivery systems and methods |
US20050080423A1 (en) * | 2003-10-09 | 2005-04-14 | Hagan Cary P. | Methods for treating osteolytic bone lesions |
US20050090904A1 (en) * | 2003-10-27 | 2005-04-28 | Howie Donald W. | Positioner and method for a femoral hip implant |
US20050090751A1 (en) * | 2000-03-28 | 2005-04-28 | Foundation For Research And Technology | Method and system for characterization and mapping of tissue lesions |
US20050094859A1 (en) * | 1999-08-10 | 2005-05-05 | Christopher Ruth | Automatic region of interest locator for AP spinal images and for hip images in bone densitometry |
US20050119746A1 (en) * | 2001-12-20 | 2005-06-02 | Lars Lidgren | Bone mineral substitute |
US20050177175A1 (en) * | 2002-04-27 | 2005-08-11 | Johnstone Alan J. | Apparatus and method for aligning and positioning implants in a body |
US20050209610A1 (en) * | 2004-03-03 | 2005-09-22 | Scimed Life Systems, Inc. | Radially adjustable tissue removal device |
US6953425B2 (en) * | 2003-04-25 | 2005-10-11 | Medtronic Vascular, Inc. | Method of treating vulnerable plaque using a catheter-based radiation system |
US20050234336A1 (en) * | 2004-03-26 | 2005-10-20 | Beckman Andrew T | Apparatus and method for marking tissue |
US20050240275A1 (en) * | 2004-04-13 | 2005-10-27 | Chappuis James L | Cannulated femoral hip implant apparatus |
US20070197954A1 (en) * | 2003-03-18 | 2007-08-23 | James Keenan | Medical devices with enhanced ultrasonic visibilty |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5681543A (en) * | 1988-02-29 | 1997-10-28 | Shering Aktiengesellschaft | Polymer-bonded complexing agents and pharmaceutical agents containing them for MRI |
ES2047376T3 (en) | 1990-04-20 | 1994-02-16 | Smith & Nephew Richards Inc | FONOCIRUGIA INSTRUMENTAL. |
US6770071B2 (en) * | 1995-06-07 | 2004-08-03 | Arthrocare Corporation | Bladed electrosurgical probe |
US6013853A (en) | 1992-02-14 | 2000-01-11 | The University Of Texas System | Continuous release polymeric implant carrier |
US5876452A (en) | 1992-02-14 | 1999-03-02 | Board Of Regents, University Of Texas System | Biodegradable implant |
US5723331A (en) | 1994-05-05 | 1998-03-03 | Genzyme Corporation | Methods and compositions for the repair of articular cartilage defects in mammals |
AU684648B2 (en) * | 1994-07-07 | 1997-12-18 | Industrial Research Limited | Ion transport apparatus and process |
US5632745A (en) | 1995-02-07 | 1997-05-27 | R&D Biologicals, Inc. | Surgical implantation of cartilage repair unit |
US6296608B1 (en) * | 1996-07-08 | 2001-10-02 | Boston Scientific Corporation | Diagnosing and performing interventional procedures on tissue in vivo |
US5921987A (en) | 1996-09-13 | 1999-07-13 | Depuy Orthopaedic Technology, Inc. | Articular cartilage transplant instrument set |
CA2274004A1 (en) | 1996-12-03 | 1998-06-11 | Osteobiologics, Inc. | Biodegradable polymeric film |
US7468075B2 (en) | 2001-05-25 | 2008-12-23 | Conformis, Inc. | Methods and compositions for articular repair |
US6146385A (en) | 1997-02-11 | 2000-11-14 | Smith & Nephew, Inc. | Repairing cartilage |
US6872819B1 (en) | 1998-05-27 | 2005-03-29 | Fidia Advanced Biopolymers S.R.L. | Biomaterials containing hyaluronic acid derivatives in the form of three-dimensional structures free from cellular components or products thereof for the in vivo regeneration of tissue cells |
DE19855890A1 (en) | 1998-12-03 | 2000-06-08 | Nerlich Michael | Porous composite matrix, its production and use |
US6270503B1 (en) | 1999-02-03 | 2001-08-07 | Arthrex, Inc. | System for ostechondral flap repair and method |
ES2235812T3 (en) | 1999-03-23 | 2005-07-16 | Zimmer Gmbh | INSTRUMENT AND SET OF INSTRUMENTS FOR THE INTRODUCTION OF AN OSTEOCARTILAGIN TRANSPLANTATION. |
WO2000075458A1 (en) * | 1999-06-07 | 2000-12-14 | Accuride International Inc. | Articulating keyboard support mechanism |
US6342075B1 (en) | 2000-02-18 | 2002-01-29 | Macarthur A. Creig | Prosthesis and methods for total knee arthroplasty |
EP1286707A2 (en) * | 2000-02-18 | 2003-03-05 | Regeneration Technologies, Inc. | Implantable tissues infused with growth factors and other additives |
US6626945B2 (en) * | 2000-03-14 | 2003-09-30 | Chondrosite, Llc | Cartilage repair plug |
US6610067B2 (en) | 2000-05-01 | 2003-08-26 | Arthrosurface, Incorporated | System and method for joint resurface repair |
US6488033B1 (en) | 2000-05-15 | 2002-12-03 | Cryolife, Inc. | Osteochondral transplant techniques |
AU7574601A (en) | 2000-07-29 | 2002-02-13 | Smith & Nephew | Tissue implant |
CA2434515A1 (en) * | 2001-01-23 | 2002-08-01 | The Regents Of The University Of California | Method and apparatus to remove substances from vessels of the heart and other parts of the body to minimize or avoid renal or other harm or dysfunction |
US20050129732A1 (en) * | 2001-07-13 | 2005-06-16 | Flow Focusing, Inc. | Biodegradable, antibiotic, controlled release tape |
US6869282B2 (en) | 2002-03-04 | 2005-03-22 | Robert P. Carmichael | Implant positioning device and method |
US7931687B2 (en) | 2002-05-13 | 2011-04-26 | Articular Engineering, Llc | Tissue engineered osteochondral implant |
WO2003106640A2 (en) | 2002-06-14 | 2003-12-24 | Case Western Reserve University | Cell targeting methods and compositions |
US7124762B2 (en) | 2002-08-15 | 2006-10-24 | Arthrex, Inc. | Dovetail meniscal allograft technique and system |
US7264634B2 (en) | 2002-09-20 | 2007-09-04 | Arthrex, Inc. | Method and instrumentation for osteochondral repair using preformed implants |
US20050124993A1 (en) | 2002-12-02 | 2005-06-09 | Chappuis James L. | Facet fusion system |
US20050222687A1 (en) | 2004-04-02 | 2005-10-06 | Gordana Vunjak-Novakovic | Cartilage implant assembly and method for implantation |
US20050064042A1 (en) | 2003-04-29 | 2005-03-24 | Musculoskeletal Transplant Foundation | Cartilage implant plug with fibrin glue and method for implantation |
US7488348B2 (en) | 2003-05-16 | 2009-02-10 | Musculoskeletal Transplant Foundation | Cartilage allograft plug |
US7901457B2 (en) | 2003-05-16 | 2011-03-08 | Musculoskeletal Transplant Foundation | Cartilage allograft plug |
US10583220B2 (en) | 2003-08-11 | 2020-03-10 | DePuy Synthes Products, Inc. | Method and apparatus for resurfacing an articular surface |
WO2005018429A2 (en) | 2003-08-20 | 2005-03-03 | Histogenics Corporation | Acellular matrix implanted into an articular cartilage or osteochondral lesion protected with a biodegradable polymer modified to have extended polymerization time and methods for preparation and use thereof |
US20050137600A1 (en) | 2003-12-23 | 2005-06-23 | Jacobs Andrew M. | Articular cartilage repair implant delivery device and method of use |
WO2005070333A1 (en) * | 2004-01-13 | 2005-08-04 | Orthobiologica, Inc. | Drug delivery to a joint |
US20050187562A1 (en) | 2004-02-03 | 2005-08-25 | Grimm James E. | Orthopaedic component inserter for use with a surgical navigation system |
US11395865B2 (en) | 2004-02-09 | 2022-07-26 | DePuy Synthes Products, Inc. | Scaffolds with viable tissue |
US20050175659A1 (en) | 2004-02-09 | 2005-08-11 | Macomber Laurel R. | Collagen device and method of preparing the same |
CA2572584A1 (en) | 2004-06-28 | 2006-01-12 | Arthrosurface, Inc. | System for articular surface replacement |
AU2006210847A1 (en) | 2005-02-01 | 2006-08-10 | Osteobiologics, Inc. | Method and device for selective addition of a bioactive agent to a multi-phase implant |
US20070129630A1 (en) * | 2005-12-07 | 2007-06-07 | Shimko Daniel A | Imaging method, device and system |
US7833269B2 (en) * | 2006-01-25 | 2010-11-16 | Warsaw Orthopedic, Inc | Osteochondral implant procedure |
-
2005
- 2005-12-07 US US11/295,639 patent/US20070129630A1/en not_active Abandoned
-
2006
- 2006-12-06 WO PCT/US2006/061666 patent/WO2007067920A2/en active Application Filing
-
2007
- 2007-10-30 US US11/927,729 patent/US20080058641A1/en not_active Abandoned
-
2008
- 2008-07-31 US US12/183,866 patent/US8795361B2/en active Active
Patent Citations (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3288140A (en) * | 1963-10-04 | 1966-11-29 | John J Mccarthy | Means for treating surface wounds |
US3982017A (en) * | 1971-02-08 | 1976-09-21 | Thiele Geraldine H | Injectable solutions and processes of using such |
US4278078A (en) * | 1980-02-26 | 1981-07-14 | Stryker Corporation | Lavage handpiece |
US4655197A (en) * | 1982-12-01 | 1987-04-07 | Snyder Laboratories, Inc. | Lavage system with variable frequency, flow rate and pressure |
US4781217A (en) * | 1985-02-13 | 1988-11-01 | Peretz Rosenberg | Pulse-irrigation method and apparatus |
US4692140A (en) * | 1985-07-01 | 1987-09-08 | Snyder Laboratories, Inc. | Lavage/suction tip with dual splash shield |
US5127920A (en) * | 1987-03-27 | 1992-07-07 | Macarthur A Creig | Prosthesis and methods for subtotal dome arthroplasty of the hip joint |
US6190642B1 (en) * | 1988-02-19 | 2001-02-20 | Dentsply Research & Development Corp. | Irrigating and lavage compositions |
US5077048A (en) * | 1988-07-13 | 1991-12-31 | Morishita Pharmaceutical Co., Ltd. | Bowel lavage composition |
US5306237A (en) * | 1989-11-06 | 1994-04-26 | Mectra Labs, Inc. | Disposable lavage |
US6471683B2 (en) * | 1990-08-06 | 2002-10-29 | Possis Medical, Inc. | Thrombectomy and tissue removal method |
US5200430A (en) * | 1991-03-21 | 1993-04-06 | Escalon Ophthalmics, Inc. | Debridement of bodily cavities using debridement fluids |
US5312385A (en) * | 1991-10-09 | 1994-05-17 | University Of Pittsburgh | Device for protected pulse irrigation |
US6001895A (en) * | 1993-03-22 | 1999-12-14 | Johnson & Johnson Medical, Inc. | Composite surgical material |
US5499970A (en) * | 1994-08-23 | 1996-03-19 | Zimmer, Inc. | Debridement tip |
US20040162488A1 (en) * | 1994-09-21 | 2004-08-19 | Medrad, Inc. | Patient specific dosing contrast delivery systems and methods |
US5931820A (en) * | 1994-12-27 | 1999-08-03 | The United States Of America As Represented By The Secretary Of The Air Force | Wound and lavage irrigation connector apparatus and method for using |
US5795324A (en) * | 1994-12-27 | 1998-08-18 | The United States Of America As Represented By The Secretary Of The Air Force | Wound and lavage irrigation cap apparatus and method for using |
US5944748A (en) * | 1996-07-25 | 1999-08-31 | Light Medicine, Inc. | Photodynamic therapy apparatus and methods |
US6569147B1 (en) * | 1996-07-26 | 2003-05-27 | Kensey Nash Corporation | Systems and methods of use for delivering beneficial agents for revascularizing stenotic bypass grafts and other occluded blood vessels and for other purposes |
US6740120B1 (en) * | 1996-08-13 | 2004-05-25 | James B. Grimes | Bone prosthesis and method of Access |
US6097978A (en) * | 1997-07-03 | 2000-08-01 | Medtronic Inc. | Measurement confirmation devices and methods for fluoroscopically directed surgery |
US5817046A (en) * | 1997-07-14 | 1998-10-06 | Delcath Systems, Inc. | Apparatus and method for isolated pelvic perfusion |
US5968017A (en) * | 1997-10-14 | 1999-10-19 | Merit Medical Systems, Inc. | Pulse fluid infusion systems |
US6364526B2 (en) * | 1997-11-26 | 2002-04-02 | Philips Medical Systems (Cleveland) Inc. | Fluoro-assist feature for a diagnostic imaging device |
US6183497B1 (en) * | 1998-05-01 | 2001-02-06 | Sub-Q, Inc. | Absorbable sponge with contrasting agent |
US6496717B2 (en) * | 1998-10-06 | 2002-12-17 | University Of South Florida | Radio guided seed localization of imaged lesions |
US20030092985A1 (en) * | 1998-10-06 | 2003-05-15 | Cox Charles E. | Radio guided seed localization of imaged lesions |
US20010018614A1 (en) * | 1999-03-16 | 2001-08-30 | Bianchi John R. | Implants for orthopedic applications |
US6726712B1 (en) * | 1999-05-14 | 2004-04-27 | Boston Scientific Scimed | Prosthesis deployment device with translucent distal end |
US20050094859A1 (en) * | 1999-08-10 | 2005-05-05 | Christopher Ruth | Automatic region of interest locator for AP spinal images and for hip images in bone densitometry |
US20030185704A1 (en) * | 2000-01-12 | 2003-10-02 | Suzanne Bernard | Physiologically balanced, ionized, acidic solution and methodology for use in wound healing |
US20050090751A1 (en) * | 2000-03-28 | 2005-04-28 | Foundation For Research And Technology | Method and system for characterization and mapping of tissue lesions |
US6635035B1 (en) * | 2000-05-02 | 2003-10-21 | Patrick V. Marasco | Tissue irrigation arrangement |
US6527760B1 (en) * | 2000-09-25 | 2003-03-04 | Vijay B. Vad | Out-patient joint lavage kit and protocol |
US20040162476A1 (en) * | 2001-06-06 | 2004-08-19 | Lars Selander | Positioning device for x-ray examinations |
US20030008011A1 (en) * | 2001-06-22 | 2003-01-09 | Mershon Millard Marsden | Compositions and methods for reducing blood and fluid loss from open wounds |
US20030105402A1 (en) * | 2001-09-12 | 2003-06-05 | Manoa Medical, Inc., A Delaware Corporation | Ultrasound imaging of breast tissue using ultrasound contrast agent |
US20050119746A1 (en) * | 2001-12-20 | 2005-06-02 | Lars Lidgren | Bone mineral substitute |
US20030163081A1 (en) * | 2002-02-28 | 2003-08-28 | Constantz Brent R. | Localized fluid delivery devices having a porous applicator and methods for using the same |
US20030229306A1 (en) * | 2002-03-29 | 2003-12-11 | Roger Sherman | Nasal lavage system and method |
US20030185903A1 (en) * | 2002-03-29 | 2003-10-02 | Jantzen Cole | Bone graft substitute composition |
US20050177175A1 (en) * | 2002-04-27 | 2005-08-11 | Johnstone Alan J. | Apparatus and method for aligning and positioning implants in a body |
US6746401B2 (en) * | 2002-05-06 | 2004-06-08 | Scimed Life Systems, Inc. | Tissue ablation visualization |
US20040059284A1 (en) * | 2002-09-24 | 2004-03-25 | Nash John E. | Interventional procedure drive and control system |
US20070197954A1 (en) * | 2003-03-18 | 2007-08-23 | James Keenan | Medical devices with enhanced ultrasonic visibilty |
US6953425B2 (en) * | 2003-04-25 | 2005-10-11 | Medtronic Vascular, Inc. | Method of treating vulnerable plaque using a catheter-based radiation system |
US6884247B1 (en) * | 2003-10-09 | 2005-04-26 | Wright Medical Technology Inc. | Methods for treating osteolytic bone lesions |
US20050080423A1 (en) * | 2003-10-09 | 2005-04-14 | Hagan Cary P. | Methods for treating osteolytic bone lesions |
US20050090904A1 (en) * | 2003-10-27 | 2005-04-28 | Howie Donald W. | Positioner and method for a femoral hip implant |
US20050209610A1 (en) * | 2004-03-03 | 2005-09-22 | Scimed Life Systems, Inc. | Radially adjustable tissue removal device |
US20050234336A1 (en) * | 2004-03-26 | 2005-10-20 | Beckman Andrew T | Apparatus and method for marking tissue |
US20050240275A1 (en) * | 2004-04-13 | 2005-10-27 | Chappuis James L | Cannulated femoral hip implant apparatus |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070129630A1 (en) * | 2005-12-07 | 2007-06-07 | Shimko Daniel A | Imaging method, device and system |
US20070135706A1 (en) * | 2005-12-13 | 2007-06-14 | Shimko Daniel A | Debridement method, device and kit |
US20120310085A1 (en) * | 2011-06-02 | 2012-12-06 | Herweck Steve A | Body lumen fluid delivery device |
WO2012166168A1 (en) * | 2011-06-02 | 2012-12-06 | Atrium Medical Corporation | Body lumen fluid delivery device |
US9327096B2 (en) * | 2011-06-02 | 2016-05-03 | Atrium Medical Corporation | Body lumen fluid delivery device |
US10357632B2 (en) | 2011-06-02 | 2019-07-23 | Atrium Medical Corporation | Body lumen fluid delivery device |
US11213652B2 (en) | 2011-06-02 | 2022-01-04 | Atrium Medical Corporation | Body lumen fluid delivery device |
US10918398B2 (en) | 2016-11-18 | 2021-02-16 | Stryker Corporation | Method and apparatus for treating a joint, including the treatment of cam-type femoroacetabular impingement in a hip joint and pincer-type femoroacetabular impingement in a hip joint |
US11612402B2 (en) | 2016-11-18 | 2023-03-28 | Stryker Corporation | Method and apparatus for treating a joint, including the treatment of cam-type femoroacetabular impingement in a hip joint and pincer-type femoroacetabular impingement in a hip joint |
US11464569B2 (en) | 2018-01-29 | 2022-10-11 | Stryker Corporation | Systems and methods for pre-operative visualization of a joint |
US11957418B2 (en) | 2022-10-10 | 2024-04-16 | Stryker Corporation | Systems and methods for pre-operative visualization of a joint |
Also Published As
Publication number | Publication date |
---|---|
WO2007067920A2 (en) | 2007-06-14 |
US8795361B2 (en) | 2014-08-05 |
US20080306608A1 (en) | 2008-12-11 |
US20070129630A1 (en) | 2007-06-07 |
US20090319051A9 (en) | 2009-12-24 |
WO2007067920A3 (en) | 2007-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080058641A1 (en) | Imaging method, device and system | |
Nilsson et al. | Hydroxyapatite coating versus cemented fixation of the tibial component in total knee arthroplasty: prospective randomized comparison of hydroxyapatite-coated and cemented tibial components with 5-year follow-up using radiostereometry | |
Halawa et al. | The shear strength of trabecular bone from the femur, and some factors affecting the shear strength of the cement-bone interface | |
KR101301862B1 (en) | Biometric sensor system for detecting biometric parameters | |
Miller | Imaging of hip arthroplasty | |
Sörensen et al. | Rapid bone and blood flow formation in impacted morselized allografts positron emission tomography (PET) studies on allografts in 5 femoral component revisions of total hip arthroplasty | |
Ranawat et al. | Fixation of the Acetabular Component: The Case for Cement. | |
Rodriguez Merchan | The haemophilic pseudotumour | |
Destouet et al. | Computed tomography of long-bone osteosarcoma | |
US20070135706A1 (en) | Debridement method, device and kit | |
Ebraheim et al. | Danger zone of the acetabulum | |
Counsell et al. | A groin mass caused by metal particle debris after hip resurfacing. | |
Kisielinski et al. | Fluordeoxyglucose positron emission tomography detection of inflammatory reactions due to polyethylene wear in total hip arthroplasty | |
US20110028981A1 (en) | Bone graft measuring apparatus and method of use | |
Pletka et al. | Biomechanical comparison of 2 different locking plate fixation methods in vancouver b1 periprosthetic femur fractures | |
Cheng et al. | Loosening of the porous coating in total knee replacement | |
Schlesinger et al. | Intracapsular osteoid osteoma of the proximal femur: findings on plain film and CT. | |
Köster et al. | Endoscopy of the femoral canal in revision arthroplasty of the hip: A new method for improving the operative technique and analysis of implant failure | |
Oyen et al. | Nuclear arthrography: combined scintigraphic and radiographic procedure for diagnosis of total hip prosthesis loosening | |
Díaz-Bertrana et al. | Interlocking nail treatment of long-bone fractures in cats: 33 cases (1995–2004) | |
Köster et al. | Clinical value of combined contrast and radionuclide arthrography in suspected loosening of hip prostheses | |
Weissman | Current topics in the radiology of joint replacement surgery | |
RU2804798C1 (en) | Set of tools and method for biological reconstruction of long bones for oncological revision knee arthroplasty | |
RYD et al. | 99mTc-diphosphonate scintigraphy in successful knee arthroplasty and its relation to micromotion. | |
Lawrie et al. | Insertion of tantalum beads in RSA of the hip variations in incidence of extra-osseous beads with insertion site |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |